Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
eczema
Biotech
Amgen reports first phase 3 win for $400M eczema drug
While the trial met its primary endpoints, Amgen still needs to make the case that there is a role for rocatinlimab in a market served by Dupixent.
Nick Paul Taylor
Sep 25, 2024 5:50am
Connect uncouples from Pfizer by scrapping eczema pact
Apr 17, 2024 6:38am
Lilly's lebrikizumab clears eczema in people with skin of color
Mar 11, 2024 9:24am
Connecting the dots: Asthma asset aces phase 2b trial
Dec 12, 2023 11:00am
California biotech Connects with Simcere in $141M licensing pact
Nov 21, 2023 11:07am
Pfizer ends 5 programs amid cost-savings overhaul
Oct 31, 2023 11:21am
